Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine.
The vaccine potential of a genetically disabled Herpes Simplex Virus Type 1 virus (DISC HSV-1) was investigated in the guinea pig model of intravaginal (i.vag.) HSV-2 infection. Three mucosal vaccination routes, i.vag., intranasal (i.n.) and oral, were compared for their ability to protect guinea pigs from challenge with wild-type HSV-2. Each was effective, particularly the i.n. route, which almost completely abolished primary disease. This was accompanied by significantly lower challenge virus titres in vaginal swabs collected from the vaccinated animals. In all cases, vaccination with the inactivated virus preparation provided substantially less protection from disease than the live DISC HSV-1 by the equivalent route. Antibody levels in serum and vaginal washes were measured both after vaccination and challenge by ELISA and neutralization tests. The highest titres were observed following administration of the DISC HSV-1 vaccine by the i.n. route. Significant increases in IgA and IgG in vaginal wash fluids were also found in these vaccinated animals.
McLean
C S
CS
Cantab Pharmaceuticals Research Ltd, Cambridge, UK.
Ni Challanáin
D
D
Duncan
I
I
Boursnell
M E
ME
Jennings
R
R
Inglis
S C
SC
D000281:Administration, Intranasal; D000284:Administration, Oral; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D004195:Disease Models, Animal; D005260:Female; D006168:Guinea Pigs; D006561:Herpes Simplex / Q000276:immunology / Q000517:prevention & control*; D018259:Herpesvirus 1, Human / Q000276:immunology* / Q000502:physiology; D018928:Immunity, Mucosal; D014621:Vagina / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*; D014779:Virus Replication / Q000276:immunology
D000914:Antibodies, Viral; D014765:Viral Vaccines